手握流感“药王”,东阳光药能否在港股续写“龙头故事”?

21世纪经济报道
Jun 12, 2025

21世纪经济报道记者唐唯珂广州报道6月11日,港交所官网显示,广东东阳光药业股份有限公司(以下简称“东阳光药”)递交了港股上市申请,拟以介绍方式在香港主板上市,中金公司担任独家保荐人。东阳光药主要聚焦于感染、慢性病及肿瘤治疗领域的药物研发、生产与商业化。公司于2024年12月首次递表港交所,这次是该公司第2次递表。东阳光药2024年营收为40.18亿元。其中磷酸奥司他韦2024年销售额为25.80...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10